
Randy Werneth, CEO and President of CardioCorX
![]()
Introducing CardioCorX, one of 21 MedTech startups chosen as finalists in the 8th annual M2D2 $200K Challenge. We spoke with CEO and President, Randy Werneth, who shared the story of their innovation.
CardioCorX was chosen for their development of a simple integrative medical approach for patients suffering from atrial fibrillation with or without heart failure.



Nuclease Probe Technologies has raised $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections. 
The
Venture financing is every entrepreneur’s goal— so every entrepreneur needs a plan to get his or her startup to the venture financing stage. That’s why M2D2 is hosting an informative happy hour:
Great news for cost-conscious medical device innovators: M2D2 is waiving the $50 entry fee for the first ten submissions to our 2019 $200K Challenge! Entries are open now—to get your application started, visit